Raymond Hoffmans is a senior executive with over 10 years of experience in clinical research. In his current capacity, he serves as head integration management officer of CATO SMS and is responsible for the integration of the legacy companies.
Prior to his current position, Hoffmans served as chief business development officer at SMS-oncology. As a member of the management team of one of the only CROs solely dedicated to oncology, he was instrumental in the continuous success and growth of SMS-oncology since 2014. In July 2019, Hoffmans also became the managing director of the German subsidiary company SMS-oncology GmbH, paving the way for international expansion and managing local clinical operations. Hoffmans started at SMS-oncology as a consultant of oncology drug development in January 2010 and led the consultancy group from October 2012 to February 2015 as director of consultancy. In these positions, he supported many clients by giving proficient advice and translating science into realistic and pragmatic clinical study designs.
Hoffmans was a postdoctoral research fellow at the Dana Farber Cancer Institute (Harvard Medical School) in Boston (2006–2009), as well as at the Hubrecht Institute in Utrecht, Netherlands (2009). Hoffmans holds a Ph.D. in natural science from the Molecular Biology Institute at the University of Zurich. He has authored multiple papers in renowned international peer-reviewed journals.